BIOTRICITY INC.

For the period ended Mar 31, 2025. Filed Jul 15, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Jul 15, 2025

BTCY$0.06+5.4%Stored close · as of Nov 13, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

Checking your notes…

	Year Ended March 31, 2025	Year Ended March 31, 2024
	$	$
REVENUE	13,790,294	12,063,345
Cost of Revenue	3,225,803	3,707,064
GROSS PROFIT	10,564,491	8,356,281
EXPENSES
Selling, general and administrative expenses	10,857,797	14,612,724
Research and development expenses	2,155,660	2,571,826
TOTAL OPERATING EXPENSES	13,013,457	17,184,550
LOSS FROM OPERATIONS	(2,448,966)	(8,828,269)
Other income/(expense) [Notes 3, 5]	(78,569)	(102,607)
Interest expense [Notes 5, 6, 7]	(3,262,038)	(3,018,803)
Gain/(Loss) upon convertible promissory notes conversion and redemption [Note 5]	(137,934)	18,539
Accretion and amortization expenses [Notes 5, 6]	(1,939,816)	(2,172,920)
Change in fair value of derivative liabilities and warrants [Note 8]	(553,856)	9,777
NET LOSS BEFORE INCOME TAXES	(8,421,179)	(14,094,283)
Income taxes [Note 10]	—	—
NET LOSS BEFORE DIVIDENDS	(8,421,179)	(14,094,283)
Preferred Stock Dividends	(466,141)	(834,677)
Deemed Dividends [Note 9]	(3,054,680)	—
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(11,942,000)	(14,928,960)
Translation adjustment	113,414	185,175
COMPREHENSIVE LOSS	(11,828,586)	(14,743,785)
LOSS PER SHARE, BASIC AND DILUTED	(0.555)	(1.660)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	21,524,884	8,991,766

BIOTRICITY, INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.